1. Home
  2. Live Updates
  3. Matthew henn

Live Breaking News & Updates on Matthew henn

Stay informed with the latest breaking news from Matthew henn on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Matthew henn and stay connected to the pulse of your community

Microbiome treatments are taking off

Faecal transplants are just the start of a new sort of medicine

San-diego , California , United-states , Italy , Belgium , Massachusetts , United-kingdom , London , City-of , Cambridge , Cambridgeshire , Netherlands

Faecal transplants are just the start of a new sort of medicine

Microbiome treatments are taking off | Science & technology

Italy , Belgium , Canada , San-diego , California , United-states , Netherlands , Massachusetts , London , City-of , United-kingdom , Cambridge

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2023 Earnings Call Transcript

Operator: Welcome to the Seres Therapeutics Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded.

Terri-young , Matthew-henn , David-arkowitz , Edward-tenthoff , Joseph-thome , Piper-sandler , Kevin-mannix , Eric-shaff , Nasdaq , American-college-of-gastroenterology , Seres-therapeutics-inc , Nestle-health-science

Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome

– Tolerability profile observed supports continued development in Cohort 2, with no treatment attributed serious adverse events –


– Reduction in incidences of microbiome pathogen... | May 9, 2023

United-states , American , Matthew-henn , International-blood , Nasdaq , American-health-drug , Marrow-transplant-research , Exchange-commission , Health-science , Seres-therapeutics-inc , Seres-therapeutics , Chief-medical-officer

Seres Therapeutics (MCRB) Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination

Seres Therapeutics (MCRB) Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , American , Matthew-henn , Exchange-commission , International-blood , Health-science , Marrow-transplant-research , Nasdaq , American-health-drug , Seres-therapeutics-inc , Wall-street , Chief-medical-officer

Fujifilm Life Sciences Showcases its Comprehensive Solutions to Support Advanced Therapies at BIO2022

Fujifilm Life Sciences Showcases its Comprehensive Solutions to Support Advanced Therapies at BIO2022
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

San-diego-convention-center , California , United-states , San-diego , Tokyo , Japan , Cambridge , Cambridgeshire , United-kingdom , Irvine , America , Christine-jackman

Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting

Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Cambridge , Cambridgeshire , United-kingdom , Matthew-henn , Kristin-ainsworth , Exchange-commission , Seres-therapeutics-inc , Drug-administration , Nasdaq , Wall-street , Disease-week , Chief-scientific-officer

Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting - Press Release

– In ECOSPOR lll, Seres' lead therapeutic candidate incorporated itself rapidly and durably into the microbiome to prevent C. difficile infection recu

Matthew-henn , Exchange-commission , Seres-therapeutics-inc , Drug-administration , Disease-week , Chief-scientific-officer , Biologics-license-application , Chief-medical-officer , Fatty-acid-production , New-england-journal , Orphan-drug , Breakthrough-therapy

Stock Market | FinancialContent Business Page

Stock Market | FinancialContent Business Page
financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.

Matthew-henn , Exchange-commission , Seres-therapeutics-inc , Drug-administration , Nasdaq , Disease-week , Chief-scientific-officer , Biologics-license-application , Chief-medical-officer , Fatty-acid-production , New-england-journal , Orphan-drug

Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting

Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting - read this article along with other careers information, tips and advice on BioSpace

Cambridge , Cambridgeshire , United-kingdom , Matthew-henn , Sloan-kettering , Elizabeth-halvorsen , Exchange-commission , Seres-therapeutics-inc , University-of-chicago , Translational-sciences-at-seres , Nasdaq , Memorial-sloan-kettering-cancer-center